EvaluatePharma, the premier source for life science sector analysis and consensus forecasts, today launched a new service enhancement, Tracking Drugs@FDA, which gives clients access to the entire universe of approved FDA drugs and the related FDA document library as well as FDA Orange Book patent data - all fully integrated into the industry-leading EvaluatePharma platform and analytical tools.

Tracking Drugs@FDA also features the standard capabilities provided by EvaluatePharma's proven platform including the ability to search and drill-down in fine detail, create and export highly customized reports and manage and receive new deeper-level data alerts via email.

Tracking Drugs@FDA is included in the latest version of the EvaluatePharma service, which covers the biotechnology and pharmaceutical sector. Visit our website to learn more about this enhancement and how you can gain access to intelligence you can act on.

About EvaluatePharma

Since 1996, EvaluatePharma has been the premier source for life science sector analysis, delivering exclusive, trusted commercial insight into industry performance through its proprietary platform. EvaluatePharma is staffed by a team of over 85 dedicated healthcare analysts employing rigorous methodologies to collate, organize and deliver the most-up-to-date commercial performance data available. An award winning editorial team of journalists writing under the EP Vantage® name support EvaluatePharma's analysis. The company's newest service offering, EvaluateMedTech™, provides the first consensus view of the medical device and diagnostic industry. The EvaluatePharma services enable the life science community to make sound business decisions about value and opportunity. For more information please visit http://www.EvaluatePharma.com.